09:51 AM EST - Valeant Pharmaceuticals International, Inc. : And Sprout Pharmaceuticals have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading down $4.20 at $316.02.
